Literature DB >> 8434357

Aerosolised ribavirin in patients with advanced cryptogenic fibrosing alveolitis: a pilot study.

C Agustí1, A Xaubet, E Ballester, A Alarcón, C Picado.   

Abstract

BACKGROUND: A report has recently been published concerning a patient with a cryptogenic fibrosing alveolitis who showed a striking improvement after being treated with the antiviral drug ribavirin (tribavirin, Virazid). The objective of this study was to further evaluate, in an open trial, the efficacy of rivabirin in cryptogenic fibrosing alveolitis.
METHODS: Ten patients (eight women) with advanced cryptogenic fibrosing alveolitis received aerosolised ribavirin (6 g/day for 15 days). Chest radiographs, lung function, and severity of dyspnoea were evaluated before and after two weeks of rivabirin treatment and also at three and 12 months.
RESULTS: No differences in radiographs, lung function impairment, or severity of dyspnoea were found after treatment. No side effects were detected.
CONCLUSIONS: Administration of high doses of aerosolised ribavirin has no beneficial effects in patients with advanced cryptogenic fibrosing alveolitis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8434357      PMCID: PMC464249          DOI: 10.1136/thx.48.1.68

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  11 in total

1.  NHLBI Workshop summary. Current concepts in idiopathic pulmonary fibrosis: a road map for the future.

Authors:  R M Cherniack; R G Crystal; A R Kalica
Journal:  Am Rev Respir Dis       Date:  1991-03

2.  Ribavirin in desquamative interstitial pneumonia.

Authors:  J Prieto; B Sangro; O Beloqui
Journal:  Chest       Date:  1988-02       Impact factor: 9.410

3.  Cryptogenic fibrosing alveolitis: pathogenetic mechanisms and therapeutic approaches.

Authors:  P L Haslam
Journal:  Eur Respir J       Date:  1990-03       Impact factor: 16.671

4.  In vitro and in vivo effects of ribavirin on human respiratory epithelium.

Authors:  L Y Han; R Wilson; S Slater; A Rutman; R C Read; N J Snell; P J Cole
Journal:  Thorax       Date:  1990-02       Impact factor: 9.139

5.  Spirometric reference values from a Mediterranean population.

Authors:  J Roca; J Sanchis; A Agusti-Vidal; F Segarra; D Navajas; R Rodriguez-Roisin; P Casan; S Sans
Journal:  Bull Eur Physiopathol Respir       Date:  1986 May-Jun

6.  Cryptogenic fibrosing alveolitis: clinical features and their influence on survival.

Authors:  M Turner-Warwick; B Burrows; A Johnson
Journal:  Thorax       Date:  1980-03       Impact factor: 9.139

7.  Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis.

Authors:  M A Johnson; S Kwan; N J Snell; A J Nunn; J H Darbyshire; M Turner-Warwick
Journal:  Thorax       Date:  1989-04       Impact factor: 9.139

8.  Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial.

Authors:  G Raghu; W J Depaso; K Cain; S P Hammar; C E Wetzel; D F Dreis; J Hutchinson; N E Pardee; R H Winterbauer
Journal:  Am Rev Respir Dis       Date:  1991-08

9.  Single-breath carbon monoxide diffusing capacity prediction equations from a Mediterranean population.

Authors:  J Roca; R Rodriguez-Roisin; E Cobo; F Burgos; J Perez; J L Clausen
Journal:  Am Rev Respir Dis       Date:  1990-04

10.  Correlation of bronchoalveolar lavage and clinical and functional findings in asbestosis.

Authors:  A Xaubet; R Rodriguez-Roisín; J A Bombí; A Marín; J Roca; A Agustí-Vidal
Journal:  Am Rev Respir Dis       Date:  1986-05
View more
  2 in total

Review 1.  Review of cryptogenic fibrosing alveolitis, including current treatment guidelines.

Authors:  S C Bourke; H Clague
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

Review 2.  New treatments for viral respiratory tract infections--opportunities and problems.

Authors:  N J Snell
Journal:  J Antimicrob Chemother       Date:  2001-03       Impact factor: 5.790

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.